

Engineering Smart Polymeric Nanosystems for Multi-Targeted Drug Delivery in Chronic Diseases

Lathamani Lakshmanan, Snehal Dasharath Pawar, Dhanasekar Jayakumar, Sudhamani Thangavel

Department of Pharmaceutics, Vivekanandha Pharmacy College, Sankari, Salem, Tamil Nadu, India - 637 303

Corresponding author Email: lathamamilakshmanan@gmail.com

Doi: <https://doi.org/10.5281/zenodo.20643326>

Received: 7 May 2026

Accepted: 17 May 2026

Abstract

Chronic diseases including cancer, diabetes mellitus, cardiovascular disorders, and neurodegenerative conditions constitute the leading cause of global morbidity and mortality, yet their pharmacological management remains constrained by the non-specific biodistribution, poor bioavailability, and systemic toxicity inherent to conventional drug delivery systems. Over the past two decades, polymeric nanosystems have emerged as a transformative platform capable of encapsulating diverse therapeutic payloads, controlling release kinetics, and navigating complex biological barriers. The concept of "smart" nanosystems extends this paradigm further: by integrating stimuli-responsive moieties sensitive to pH, temperature, redox gradients, or enzymatic activity these carriers can achieve spatiotemporal precision in drug release that conventional systems cannot approximate. Multi-targeted strategies, combining passive accumulation via the enhanced permeability and retention (EPR) effect with active ligand–receptor recognition and intracellular delivery mechanisms, offer the prospect of simultaneously addressing multiple pathological pathways within a single nanoscale architecture. This review synthesizes the current literature on the design, engineering, preparation, and characterization of smart polymeric nanosystems, and critically evaluates their therapeutic applications across major chronic diseases. We examine recent advances including AI-assisted polymer design, theranostic integration, and hybrid nanocarrier architectures, while honestly appraising the translational challenges of scale-up manufacturing, regulatory complexity, and clinical validation. Looking forward, the convergence of smart polymeric nanotechnology with personalized medicine, gene therapy, and bioelectronics portends a paradigm shift toward truly adaptive, patient-specific therapeutic systems.

Keywords: Polymeric nanoparticles, Smart drug delivery, Chronic diseases, Targeted therapy, Nanomedicine, Controlled release

1. Introduction

Chronic diseases encompassing cancers, diabetes mellitus, and cardiovascular disorders, neurodegenerative conditions such as Alzheimer's and Parkinson's disease, and chronic inflammatory

diseases including ulcerative colitis collectively account for the majority of healthcare expenditure worldwide and impose an immense burden on patients and health systems alike. These conditions typically require long-term, often lifelong, pharmacological intervention, yet conventional drug delivery approaches oral tablets, intravenous injections, and topical formulations are fundamentally limited by non-specific biodistribution, rapid clearance, plasma-level fluctuations, and dose-limiting systemic toxicity [1]. The emergence of nanotechnology-based drug delivery systems has catalyzed a fundamental re-imagining of therapeutic design. Polymeric nanosystems, in particular, offer a versatile and tunable platform: their nanoscale dimensions (typically 10–1000 nm), high surface-area-to-volume ratio, and amenability to chemical functionalization enable enhanced cellular uptake, prolonged circulation, and preferential accumulation at pathological sites 2. Biodegradable and biocompatible polymers such as poly(lactic-co-glycolic acid) (PLGA), chitosan, poly(ethylene glycol) (PEG), and polycaprolactone serve as the foundational materials, their degradation profiles and release kinetics being precisely tunable through copolymer composition and molecular weight [2]. The concept of "smart" nanosystems represents a qualitative advance beyond passive nanoencapsulation. Smart polymeric systems are engineered to respond to specific chemical, biochemical, physical, or mechanical stimuli including pH gradients, temperature shifts, redox potential, enzymatic activity, electric or magnetic fields by undergoing conformational changes, swelling, degradation, or disassembly that trigger controlled drug release at the target site 3, 4. This stimulus-responsive capacity transforms the drug carrier from a passive vehicle into an active therapeutic partner. Furthermore, the multi-targeted strategy addresses the inherent complexity of chronic disease pathophysiology, where multiple molecular pathways and cell populations contribute to disease progression. By combining passive targeting (EPR effect), active targeting (ligand-decorated surfaces), and multi-drug co-loading, polymeric nanosystems can simultaneously engage several therapeutic targets, overcoming drug resistance and improving synergistic efficacy 5, 6. This review aims to provide a comprehensive yet critically oriented synthesis of the engineering principles, mechanistic foundations, and therapeutic applications of smart polymeric nanosystems for multi-targeted drug delivery in chronic diseases, while candidly assessing the translational hurdles that remain.

2. Overview of Polymeric nanosystems

2.1 Definition

Polymeric nanosystems are nanoscale drug delivery architectures constructed from natural, synthetic, or semi-synthetic polymers, designed to encapsulate, protect, transport, and release therapeutic agents in a controlled manner [7].

2.2 Types




Figure 1: Polymeric nanosystems classification

Polymeric nanoparticles - including nanospheres and nanocapsules represent the most widely investigated class. Drugs may be dispersed throughout a polymeric matrix (nanospheres) or confined within a polymeric shell surrounding a core (nanocapsules), offering distinct release profiles [7].

Polymeric micelles - are self-assembled core-shell structures formed from amphiphilic block copolymers. The hydrophobic core solubilizes poorly water-soluble drugs, while the hydrophilic corona confers colloidal stability and stealth properties (Figure 1) [8, 9.]

Dendrimers are hyperbranched, monodisperse macromolecules with precisely defined architecture, offering multivalent surface functionalization and internal cavities for drug entrapment [10].

Hydrogels are three-dimensional, cross-linked polymeric networks capable of absorbing large quantities of water while retaining structural integrity. Stimuli-responsive nanogels, in particular, have attracted significant attention for controlled and triggered drug release [11].

Biodegradable and biocompatible polymers (e.g., PLGA, chitosan, PEG) PLGA remains the most extensively studied biodegradable polymer for nanosystem fabrication, with its lactic-to-glycolic acid ratio enabling precise control over degradation kinetics and release timelines [2]. Chitosan, a natural polycationic polysaccharide, offers mucoadhesive properties advantageous for mucosal and oral delivery [12]. PEG is universally employed for "stealth" surface coating, extending circulation half-life by reducing opsonization and reticuloendothelial system clearance (Figure 2).




Figure 2: Different types of polymeric nanosystems

2. Design and engineering of Smart nanosystems

The engineering of smart polymeric nanosystems involves deliberate architectural decisions at the molecular, supramolecular, and systems levels.

3.1 Surface modification (PEGylation, ligand attachment) Covalent grafting of PEG chains onto nanoparticle surfaces remains the gold standard for conferring "stealth" character, reducing protein corona formation and prolonging systemic circulation [13].

3.2 Functionalization for targeting Ligands including antibodies, peptides, aptamers, and small molecules such as folate are conjugated to nanocarrier surfaces to enable receptor-mediated endocytosis at target cells, enhancing specificity and reducing off-target effects (Figure 3) [5].




Figure 3: Engineering of Smart polymeric nanosystems

3.3 Controlled and sustained release design Polymer composition, molecular weight, cross-linking density, and matrix architecture are systematically varied to achieve desired release profiles, from zero-order sustained release to pulsatile delivery [14].

3.4 Multi-drug loading strategies Co-encapsulation of multiple therapeutic agents — chemotherapeutic combinations, drug–gene pairs, or drug–imaging agent theranostic constructs — within a single nanosystem enables synergistic multi-pathway targeting [15].

3.5 Stimuli-responsive design (pH, temperature, enzymes, redox) - pH-responsive polymers (exploiting acidic tumor microenvironments or endosomal pH), thermoresponsive polymers (leveraging localized hyperthermia), redox-sensitive linkages (cleaved by elevated intracellular glutathione), and enzyme-degradable segments collectively enable on-demand, site-specific drug release [4].

4. Mechanism of multi-targeted drug delivery

4.1 Passive targeting

It exploits the EPR effect, wherein the leaky vasculature and impaired lymphatic drainage characteristic of solid tumors and inflamed tissues permit preferential nanoparticle accumulation [13].

4.2 Active targeting

It employs surface-conjugated ligands that bind overexpressed receptors on diseased cells folate receptors on tumors, transferrin receptors on brain endothelium, or asialoglycoprotein receptors on hepatocytes facilitating receptor-mediated endocytosis and intracellular delivery (Figure 4) [5, 6].

4.3 Dual and multi-targeting strategies

This combine these approaches: for instance, a PEGylated, folate-decorated, pH-sensitive polymeric micelle achieves long circulation (stealth), tumor accumulation (EPR), cell-specific uptake (folate receptor), and triggered intracellular release (endosomal pH) [16].

4.4 Intracellular drug delivery

This mechanisms involve endosomal escape (proton-sponge effect, fusogenic peptides), cytoplasmic release, and nuclear targeting, ensuring that therapeutic payloads reach their subcellular sites of action [10, 17].




Figure 4: Mechanism of multi-targeted drug delivery

5. Methods of preparation

- Emulsion-solvent evaporation
- Nanoprecipitation
- Ionic gelation
- Self-assembly techniques
- Microfluidics

Fabrication methodology profoundly influences nanosystem properties. Emulsion-solvent evaporation remains widely employed for PLGA nanoparticles, enabling control over particle size through emulsification energy and surfactant concentration [3]. Nanoprecipitation (solvent displacement) offers simplicity and narrow size distributions. Ionic gelation, particularly for chitosan-based systems, exploits electrostatic cross-linking with polyanions such as tripolyphosphate. Self-assembly of amphiphilic block copolymers yields micelles and polymersomes with thermodynamically defined architectures (Figure 5) [8, 9]. Microfluidic techniques represent a recent advance, offering precise control over mixing conditions and enabling reproducible, scalable nanoparticle synthesis [18].




Figure 5: Preparation methods of Polymeric nanosystems

6. Characterization techniques

- ✓ Particle size, PDI, zeta potential
- ✓ Morphology (SEM, TEM)
- ✓ Drug loading & encapsulation efficiency
- ✓ In vitro drug release studies
- ✓ Stability and degradation analysis

Rigorous characterization is essential for quality control and regulatory approval. Particle size, polydispersity index (PDI), and zeta potential are routinely measured by dynamic light scattering. Morphology is assessed via scanning and transmission electron microscopy (SEM, TEM). Drug loading and encapsulation efficiency are quantified by spectroscopic or chromatographic methods. In vitro drug release studies under simulated physiological conditions (varying pH, temperature, enzyme concentrations) elucidate release kinetics and stimulus-responsiveness. 7. Stability and degradation analysis encompassing shelf-life, accelerated degradation, and in vivo biodistribution are critical for translational advancement (Table 1) [19].

Table 1: Characterization parameters of Polymeric nanosystems for drug delivery: Critical parameters & Ideal values

Characterization Parameter	Assessment Method(s) & Mechanism	Critical for (As described in text)	Representative Ideal Values / Ranges for Polymeric Nanosystems
Particle Size (z-average)	Dynamic Light Scattering (DLS)	- Routinely measured - Quality control - Regulatory approval	10–200 nm (Typically <150 nm to minimize filtration by liver and spleen, maximize circulation time)
Polydispersity Index (PDI)	DLS	- Routinely measured - Quality control - Regulatory approval	<0.2 (Indicates narrow, uniform size distribution; critical for reproducibility)
Zeta Potential	DLS	- Routinely measured - Quality control - Regulatory approval	±30 mV or higher (Indicates good colloidal stability and reduced aggregation)
Morphology	Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM)	Assessed via SEM/TEM	Spherical and uniform (Minimal aggregation/deformed particles)
Drug Loading (DL)	Spectroscopic (UV-Vis) or Chromatographic (HPLC) methods	Quantified by spectroscopic/ chromatographic methods	>10% (Ideally maximized to reduce polymer dose needed)
Encapsulation Efficiency (EE)	Spectroscopic (UV-Vis) or Chromatographic (HPLC) methods	Quantified by spectroscopic/ chromatographic methods	>80% (Ideally minimized initial burst, highly efficient payload capture)
In vitro Drug Release Studies	Simulating physiological conditions (varying pH, temperature, enzyme concentrations)	- Elucidate release kinetics and stimulus-responsiveness - Critical for regulatory approval	Sustained, stimuli-responsive, or zero-order (Application-dependent, minimal burst, predictable kinetics)
Stability & Degradation Analysis	Shelf-life, accelerated degradation, and in vivo biodistribution	- Translational advancement - Shelf-life and in vivo safety	Prolonged shelf-life (>1 year) and controlled degradation (Application-dependent, in vivo clearance without accumulation)

*Note: 'Ideal' values can vary depending on the intended therapeutic application and route of administration.

Based on 'Smart Polymeric Nanosystems' section

7. Applications in chronic diseases

7.1 Cancer

Cancer therapy represents the most extensively investigated application. Smart polymeric nanosystems enable targeted chemotherapy delivery, reducing cardiotoxicity (e.g., doxorubicin-loaded systems) and overcoming multidrug resistance through combination therapy and stimuli-triggered release [16, 17, 20]. Multi-drug loaded nanosystems co-delivering chemotherapeutic agents with immunomodulators or gene silencing agents (siRNA) exemplify the multi-targeted paradigm [15].

7.2 Diabetes Mellitus

Controlled insulin delivery via polymeric nanosystems addresses the challenges of insulin's instability, short half-life, and susceptibility to gastrointestinal degradation. Glucose-responsive "smart" systems that release insulin in proportion to blood glucose levels represent a frontier toward closed-loop artificial pancreas concepts [3, 21].

7.3 Cardiovascular Diseases

Targeted delivery to vascular tissues inflamed endothelium, atherosclerotic plaques employs nanosystems functionalized with ligands for endothelial adhesion molecules, enabling site-specific anti-inflammatory or anti-proliferative therapy [1].

7.4 Neurodegenerative Disorders

Crossing the blood-brain barrier (BBB) remains a formidable challenge. Polymeric nanoparticles surface-modified with transferrin, lactoferrin, or cell-penetrating peptides have demonstrated enhanced BBB transcytosis in preclinical models [6, 12].

7.5 Inflammatory Diseases

Site-specific delivery for ulcerative colitis exemplifies the integration of pH-responsive and enzyme-responsive design: nanosystems remain intact through gastric transit and selectively release anti-inflammatory agents in the colonic microenvironment [2, 22].

8. Role in Personalized medicine

The convergence of smart polymeric nanosystems with precision medicine is reshaping therapeutic paradigms. Biomarker-based delivery where nanocarrier surface ligands are selected according to a patient's tumor receptor profile enables truly patient-specific targeting [8]. Biosensor-integrated drug delivery systems, coupling continuous biological monitoring with automated drug administration, represent the frontier of closed-loop personalized therapy, particularly for diabetes and cardiovascular management [21].

9. Advantages

Smart polymeric nanosystems confer multiple therapeutic advantages: enhanced bioavailability of poorly soluble drugs through nanoencapsulation; site-specific targeting that maximizes therapeutic concentration at the disease locus while minimizing systemic exposure; reduced toxicity and adverse effects; sustained and controlled drug release that diminishes dosing frequency and plasma-level fluctuations; and improved patient compliance [23, 24].

10. Limitations and challenges

Despite their promise, several formidable challenges impede clinical translation. Polymer toxicity concerns particularly for non-biodegradable or cationic polymers necessitate rigorous biocompatibility

assessment 25. Scale-up and manufacturing difficulties represent perhaps the most critical bottleneck: laboratory-scale synthesis methods often fail to maintain batch-to-batch reproducibility, particle size uniformity, and drug loading consistency at industrial scale 19, 18, 26. Stability issues — aggregation, premature drug leakage, and degradation during storage further complicate formulation development. Regulatory barriers are substantial, as the unique physicochemical properties of nanomedicines demand characterization standards and safety evaluation paradigms that existing frameworks inadequately address 19. Cost considerations associated with complex multi-step synthesis and characterization remain a practical obstacle to commercial viability 26.

11. Recent advances

The field has witnessed transformative advances in recent years. Stimuli-responsive "smart" polymers have evolved from single-stimulus to multi-stimuli responsive architectures capable of sequential or synergistic triggered release 25, 17. Dual-drug loaded nanosystems co-encapsulating synergistic drug combinations enable simultaneous multi-pathway targeting 15, 9. AI-assisted formulation design is accelerating polymer selection, structure–property prediction, and optimization of nanocarrier parameters, reducing the empiricism traditionally dominating formulation development 25. Hybrid polymeric nanocarriers integrating polymeric, lipidic, and inorganic components expand functional versatility 13. Theranostic applications systems simultaneously capable of therapeutic delivery and diagnostic imaging enable real-time treatment monitoring and represent a paradigm of multifunctional nanosystem design 21.

12. Future perspectives

Clinical translation remains the paramount challenge and opportunity. Moving polymeric nanosystems from bench to bedside requires not only scientific advances but also harmonized regulatory frameworks, standardized characterization protocols, and scalable manufacturing processes 19. Advanced multifunctional nanosystems combining targeting, imaging, and multi-drug delivery within a single platform will increasingly approximate the complexity of disease pathophysiology. Integration with gene therapy and biologics including mRNA delivery, CRISPR-Cas9 systems, and protein therapeutics expands the therapeutic repertoire of polymeric nanosystems beyond small molecules 5. The incorporation of bioelectronics and biosensor feedback loops into polymeric delivery platforms portends truly autonomous, closed-loop therapeutic systems 21, 25. Regulatory science must evolve in parallel, developing nanomedicine-specific guidelines that balance innovation with patient safety.

13. Conclusion

Smart polymeric nanosystems represent a paradigmatic advance in drug delivery science, transitioning the field from passive encapsulation to active, stimulus-responsive, multi-targeted therapeutic architectures. By integrating biodegradable polymer chemistry, surface engineering, and stimuli-responsive design, these systems address the fundamental limitations of conventional drug delivery non-specificity, toxicity, and poor bioavailability that have long constrained the management of chronic diseases. Their applications now span cancer, diabetes, cardiovascular and neurodegenerative disorders, and inflammatory diseases, with emerging roles in personalized and precision medicine. The recent convergence of AI-driven design, theranostic integration, and hybrid nanocarrier engineering has further accelerated the field's trajectory. Nevertheless, the translational gap between laboratory innovation and

clinical realization remains substantial, demanding concerted advances in scalable manufacturing, regulatory harmonization, and long-term safety evaluation. Future research must prioritize not merely novel materials or architectures, but the systematic resolution of these translational barriers, ensuring that the extraordinary therapeutic potential of smart polymeric nanosystems is realized for patients with chronic diseases worldwide.

References

1. Liu, D., Yang, F., Xiong, F., & Gu, N. (2016). The Smart Drug Delivery System and Its Clinical Potential. *Theranostics*, 6(9), 1306–1323. <https://doi.org/10.7150/thno.14858>
2. Zeb, A., Gul, M., Nguyen, T.-T.-L., & Maeng, H.-J. (2022). Controlled release and targeted drug delivery with poly(lactic-co-glycolic acid) nanoparticles: reviewing two decades of research. *Journal of Pharmaceutical Investigation*, 52(6), 683–724. <https://doi.org/10.1007/s40005-022-00584-w>
3. El-Sherbiny, I., Khalil, I., Ali, I., & Yacoub, M. (2017). Updates on smart polymeric carrier systems for protein delivery. *Drug Development and Industrial Pharmacy*, 43(10), 1567–1583. <https://doi.org/10.1080/03639045.2017.1338723>
4. Wells, C. M., Harris, M., Choi, L., Murali, V. P., Guerra, F. D., & Jennings, J. A. (2019). Stimuli-Responsive Drug Release from Smart Polymers. *Journal of Functional Biomaterials*, 10(3), 34. <https://doi.org/10.3390/jfb10030034>
5. Wells, C. M., Harris, M., Choi, L., Murali, V. P., Guerra, F. D., & Jennings, J. A. (2019). Stimuli-Responsive Drug Release from Smart Polymers. *Journal of Functional Biomaterials*, 10(3), 34. <https://doi.org/10.3390/jfb10030034>
6. Taneja, A., Panda, H. S., Panda, J. J., Singh, T. G., & Kour, A. (2025). Revolutionizing Precision Medicine: Unveiling Smart Stimuli-Responsive Nanomedicine. *Advanced Therapeutics*, 8(8). <https://doi.org/10.1002/adtp.202500073>
7. Castro, K. C. de, Costa, J. M., & Campos, M. G. N. (2020). Drug-loaded polymeric nanoparticles: a review. *International Journal of Polymeric Materials and Polymeric Biomaterials*, 71(1), 1–13. <https://doi.org/10.1080/00914037.2020.1798436>
8. Bryaskova, R. G., Staykov, K. G., & Ganchev, D. S. (2026). Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems. *Pharmaceutics*, 18(2), 177. <https://doi.org/10.3390/pharmaceutics18020177>
9. Shahriari, M., Torchilin, V. P., Taghdisi, S. M., Abnous, K., Ramezani, M., & Alibolandi, M. (2020). “Smart” self-assembled structures: toward intelligent dual responsive drug delivery systems. *Biomaterials Science*, 8(21), 5787–5803. <https://doi.org/10.1039/d0bm01283a>
10. Handa, M., Singh, A., Flora, S. J. S., & Shukla, R. (2022). Stimuli-responsive Polymeric Nanosystems for Therapeutic Applications. *Current Pharmaceutical Design*, 28(11), 910–921. <https://doi.org/10.2174/1381612827666211208150210>
11. Hajebi, S., Rabiee, N., Bagherzadeh, M., Ahmadi, S., Rabiee, M., Roghani-Mamaqani, H., Tahriri, M., Tayebi, L., & Hamblin, M. R. (2019). Stimulus-responsive polymeric nanogels as smart drug delivery systems. *Acta Biomaterialia*, 92, 1–18. <https://doi.org/10.1016/j.actbio.2019.05.018>
12. Ramasamy, T., Ruttala, H. B., Gupta, B., Poudel, B. K., Choi, H.-G., Yong, C. S., & Kim, J. O. (2017). Smart chemistry-based nanosized drug delivery systems for systemic applications: A comprehensive review. *Journal of Controlled Release*, 258, 226–253. <https://doi.org/10.1016/j.jconrel.2017.04.043>
13. Li, X., Gao, Y., Li, H., Majoral, J.-P., Shi, X., & Pich, A. (2023). Smart and bioinspired systems for overcoming biological barriers and enhancing disease theranostics. *Progress in Materials Science*, 140, 101170. <https://doi.org/10.1016/j.pmatsci.2023.101170>
14. du Toit, L. C., Choonara, Y. E., Kumar, P., & Pillay, V. (2016). Polymeric networks for controlled release of drugs: a patent review. *Expert Opinion on Therapeutic Patents*, 26(6), 703–717. <https://doi.org/10.1080/13543776.2016.1178720>
15. Paul, S., Mukherjee, S., & Banerjee, P. (2023). Recent advancement in nanomaterial-encapsulated drug delivery vehicles for combating cancer, COVID-19, and HIV-like chronic diseases. *Materials Advances*, 4(9), 2042–2061. <https://doi.org/10.1039/d2ma01075e>
16. Hong, T., Shen, X., Syeda, M. Z., Zhang, Y., Sheng, H., Zhou, Y., Xu, J., Zhu, C., Li, H., Gu, Z., & Tang, L. (2022). Recent advances of bioresponsive polymeric nanomedicine for cancer therapy. *Nano Research*, 16(2), 2660–2671. <https://doi.org/10.1007/s12274-022-5002-2>

17. Fatima, M., Almalki, W. H., Khan, T., Sahebkar, A., & Kesharwani, P. (2024). Harnessing the Power of Stimuli-Responsive Nanoparticles as an Effective Therapeutic Drug Delivery System. *Advanced Materials*, 36(24). <https://doi.org/10.1002/adma.202312939>
18. Mahmud, Md. M., Pandey, N., Winkles, J. A., Woodworth, G. F., & Kim, A. J. (2024). Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials. *Nano Today*, 56, 102314. <https://doi.org/10.1016/j.nantod.2024.102314>
19. Hua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G. (2018). Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization. *Frontiers in Pharmacology*, 9. <https://doi.org/10.3389/fphar.2018.00790>
20. Alsuraifi, A., Curtis, A., Lamprou, D. A., & Hoskins, C. (2018). Stimuli Responsive Polymeric Systems for Cancer Therapy. *Pharmaceutics*, 10(3), 136. <https://doi.org/10.3390/pharmaceutics10030136>
21. Cicha, I., Priefer, R., Severino, P., Souto, E. B., & Jain, S. (2022). Biosensor-Integrated Drug Delivery Systems as New Materials for Biomedical Applications. *Biomolecules*, 12(9), 1198. <https://doi.org/10.3390/biom12091198>
22. Hua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G. (2018). Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization. *Frontiers in Pharmacology*, 9. <https://doi.org/10.3389/fphar.2018.00790>
23. Zhu, Y., Wu, T., Fu, Y., Cheng, Z., Zhu, M., Lv, Y., Nie, C., Zheng, P., & Qiao, D. (2026). Smart oral delivery of curcumin nanoparticulate systems for targeted colorectal cancer therapy: strategies, applications, and future perspectives. *Nanomedicine*, 1–36. <https://doi.org/10.1080/17435889.2026.2650486>
24. Chen, M., Lan, H., Jin, K., & Chen, Y. (2023). Responsive nanosystems for targeted therapy of ulcerative colitis: Current practices and future perspectives. *Drug Delivery*, 30(1). <https://doi.org/10.1080/10717544.2023.2219427>
25. Kaur Minhas, J., Aher, V. D., Bujji, S., Chaudhari, H. C., Mohammed, I. A., Bhise, M. R., Tiwari, G., & Sharma, P. (2025). Engineering Polymers: From Biodegradable Platforms to Intelligent Drug Carriers. *Polymer-Plastics Technology and Materials*, 64(12), 1883–1909. <https://doi.org/10.1080/25740881.2025.2487888>
26. Agrahari, V., & Agrahari, V. (2018). Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities. *Drug Discovery Today*, 23(5), 974–991. <https://doi.org/10.1016/j.drudis.2018.01.047>